Opioid use disorder - Prevention Strategies and Policy

Prevention Strategies for Opioid Overdose and Misuse Introduction: Why Prevention Matters The United States faces a critical public health challenge with opioid-related overdose deaths rising dramatically. Prevention strategies work at multiple levels: reducing unnecessary opioid exposure through careful prescribing, ensuring that overdose reversal medications are accessible when overdoses do occur, and building broader public health systems to identify and support people at risk. This chapter covers the key clinical and public health approaches to preventing opioid harms. Prescribing Guidelines: Starting with the Lowest Dose The foundation of preventing opioid misuse begins at the prescribing level. The Centers for Disease Control and Prevention (CDC) clinical practice guidelines recommend that clinicians prescribe the lowest effective dose of immediate-release opioids for the shortest duration necessary, particularly for patients who have never taken opioids before (opioid-naïve patients). This approach reduces unnecessary exposure to opioids while still allowing patients with legitimate pain to receive adequate treatment. When possible, clinicians should use non-opioid pain management strategies first—such as physical therapy, over-the-counter medications, or other pain management approaches—before turning to opioids. The goal is to balance pain management with safety. Screening and Risk Identification Before prescribing opioids, screening for risk factors can help identify which patients are at higher risk for opioid misuse. One important screening tool involves asking about adverse childhood experiences (ACEs), such as trauma, abuse, or substance use in the home. Individuals with ACEs are at elevated risk for substance use disorders later in life, so identifying them early allows clinicians to use extra caution when prescribing and to offer additional support or non-opioid alternatives when possible. Alongside clinical screening, public education campaigns—including community outreach and school-based programs—inform people about the risks of prescription opioids and illegal substances like fentanyl, helping people make informed decisions about their health. Naloxone: The Overdose Reversal Medication How Naloxone Works Naloxone is a competitive opioid receptor antagonist. This means it binds to the same receptors in the brain that opioids bind to, but it does not activate them. Instead, naloxone displaces opioids that are already bound to these receptors, rapidly reversing the effects of opioid overdose, particularly the life-threatening respiratory depression (slowed or stopped breathing). Naloxone works quickly—typically within minutes of administration—making it critical for emergency use when someone is overdosing. Routes of Administration Naloxone can be delivered through multiple methods, which has improved its accessibility: Intranasal (nasal spray): The most widely distributed form in the United States; easy for laypersons to use without special training Intramuscular (IM injection): Injected into muscle tissue Intravenous (IV injection): Injected directly into a vein; used in medical settings for rapid effects Subcutaneous: Injected under the skin Inhalation: Inhaled powder form The intranasal and IM forms are most practical for community use because they do not require special skills or equipment. Naloxone Distribution and Access Who Should Have Naloxone? Guidelines recommend naloxone kits be available to several groups: Laypersons likely to witness an overdose: This includes family members and friends of people who use opioids Patients with large opioid prescriptions: Those taking higher doses are at greater overdose risk Individuals in substance-use treatment: People in recovery may still be at risk Those recently released from incarceration: Overdose risk is particularly high immediately after release Making Naloxone Accessible Several policy changes have dramatically increased naloxone access: Pharmacy standing orders: Many states now allow pharmacists to dispense naloxone directly to customers without an individual prescription. This "standing order" system means anyone can walk into a pharmacy and request naloxone. Good Samaritan laws: Most U.S. states have enacted laws that protect bystanders who administer naloxone from legal prosecution, removing a major barrier to use. Community-based programs: Overdose prevention programs distribute naloxone kits to law-enforcement officers, first responders, and community members. Training and Recognition Alongside naloxone distribution, training programs teach people to recognize overdose signs—such as unresponsiveness, gasping, and slow or stopped breathing—and to administer naloxone safely and confidently. Broader Public Health Systems Prescription Drug Monitoring Programs Prescription drug monitoring programs (PDMPs) are databases that track prescriptions of controlled substances across a state or region. Pharmacists and clinicians can check these databases to identify patients who may be receiving excessive opioids from multiple providers—a key sign of misuse. These programs help prevent "doctor shopping," where patients visit multiple clinicians to obtain more opioids. Retail Pharmacy Protocols Major pharmacy chains have implemented systematic protocols including: Unused opioid take-back programs: Allow patients to safely dispose of leftover medications Naloxone distribution: Stock and promote naloxone availability Monitoring of suspicious prescriptions: Flagging prescriptions that appear unusual or excessive Insurance and Quantity Limits Insurance programs often set quantity limits on opioid prescriptions or require prior authorizations, meaning the prescriber must justify the prescription to the insurance company before it's approved. These measures reduce unnecessary prescribing. Harm-Reduction Approaches Harm reduction recognizes that while preventing all drug use is ideal, reducing the harms associated with drug use is a crucial intermediate goal. Key harm-reduction strategies include: Needle-exchange programs: Reduce transmission of HIV and hepatitis C among people who inject drugs by providing clean needles and safe injection supplies Medication-assisted treatment: Using medications like buprenorphine or methadone to reduce cravings and withdrawal, allowing people to stabilize and reduce illicit use Supervised consumption sites: In some jurisdictions, medically supervised spaces where people can use pre-obtained drugs with medical staff present to prevent overdoses These approaches are based on evidence that they reduce both disease transmission and overdose deaths. Major Policy Changes and Guidelines The 2022 and 2023 CDC Guidelines The CDC has released updated clinical practice guidelines for opioid prescribing: 2022 guideline: Recommends the lowest effective opioid dose for the shortest duration 2023 guideline: Expands recommendations to include safe monitoring and tapering of opioids (gradually reducing the dose for patients already taking chronic opioids) These guidelines are based on evidence about safe prescribing and represent a shift toward more conservative, evidence-based opioid use. The MAT Act (2023) The Medication Assisted Treatment (MAT) Act of 2023 eliminated the "waiver" requirement that clinicians previously needed to prescribe buprenorphine for opioid use disorder. This change dramatically expands treatment access by allowing more clinicians to prescribe this life-saving medication without additional credentialing. This is significant because buprenorphine is one of the most effective treatments for opioid addiction. Telehealth Expansion Federal agencies have authorized the use of telehealth for medication-assisted treatment, including remote initiation and continuation of buprenorphine and methadone. This was particularly important during the COVID-19 pandemic and has remained in place, improving access for people in rural areas or those with transportation barriers. Education and Stigma Reduction National campaigns aim to decrease stigma surrounding substance-use disorders, which is critical because stigma often prevents people from seeking treatment. When substance use is viewed as a moral failing rather than a medical condition, people delay seeking care and face barriers to employment and social support. Reducing stigma through education improves willingness to seek treatment and engage with healthcare systems. Data-Driven Resource Allocation Public health agencies conduct ongoing surveillance of overdose trends and drug-involved deaths. This data guides where resources should be focused—for example, if a particular region experiences a spike in fentanyl-related overdoses, resources can be directed there for increased naloxone distribution and education. This targeted, data-driven approach to public health is more effective than broad, untargeted interventions. Summary Prevention of opioid overdose and misuse involves coordinated strategies at multiple levels: controlled prescribing practices that minimize unnecessary opioid exposure, accessible overdose reversal medications for emergencies, public health infrastructure to monitor and respond to trends, and policies that expand treatment access. These approaches work together to reduce overdose deaths while still ensuring that people with legitimate pain can access appropriate treatment.